Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Completed Not applicable Interventional

Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting

NCT01582841
View directory record Official record
Conditions
Colon Cancer, Lynch Syndrome
Interventions
MSI screening test
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 16, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

NCT03404193
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Decitabine, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

NCT01497184
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
HSCT, DLI
Procedure · Genetic
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 16, 2026, 9:17 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

NCT04030455
View directory record Official record
Conditions
Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Docetaxel, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Recruiting Phase 2 Interventional

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT05645718
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Not applicable Interventional

A Culturally Sensitive Social Support Intervention

NCT02946697
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Social support intervention
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 16, 2026, 9:17 AM EDT
Recruiting No phase listed Observational

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

NCT02726750
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Irinotecan (Camptosar) in Patients With Advanced Sarcomas

NCT00509860
View directory record Official record
Conditions
Sarcoma
Interventions
Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 16, 2026, 9:17 AM EDT
Not yet recruiting Not applicable Interventional

iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer

NCT07105020
View directory record Official record
Conditions
Prostate Cancer
Interventions
Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Completed No phase listed Observational

Conjoint Analysis of Treatment Preferences for Osteoarthritis

NCT01003925
View directory record Official record
Conditions
Osteoarthritis
Interventions
Standard of care for osteoarthritis treatment, Conjoint Analysis for Osteoarthritis
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
65 Years to 95 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

NCT00075010
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Valproic acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 16, 2026, 9:17 AM EDT
Active, not recruiting Not applicable Interventional

Sleep and Physical Activity Intervention for Increasing Physical Activity in Overweight or Obese and Sedentary African Americans

NCT04236882
View directory record Official record
Conditions
Behavioral Disorder, Endocrine System Disorder
Interventions
Focus Group, Health Education, Internet-Based Intervention, Interview, Questionnaire Administration
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer

NCT03491176
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Healthy Subject, Head and Neck Cancer
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Completed No phase listed Observational

Automated Pain Intervention for Underserved Minority Breast Cancer Patients

NCT00881010
View directory record Official record
Conditions
Breast Cancer
Interventions
Telephone Intervention, Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 16, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

NCT03799445
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Posterior Tongue Squamous Cell Carcinoma, Soft Palate Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Tonsillar Squamous Cell Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Withdrawn No phase listed Observational

Intraoperative Optical Imaging of Brain Function

NCT00632437
View directory record Official record
Conditions
Brain Tumor
Interventions
Speckle-Contrast Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 16, 2026, 9:17 AM EDT
Not listed Phase 2 Interventional Results available

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

NCT03094637
View directory record Official record
Conditions
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome
Interventions
Azacitidine, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 16, 2026, 9:17 AM EDT
Active, not recruiting Not applicable Interventional

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03114501
View directory record Official record
Conditions
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Head and Neck Cancer
Interventions
Yoga, Yoga Questionnaire, Symptom Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

NCT01919619
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
Interventions
Ipilimumab, Lenalidomide
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 16, 2026, 9:17 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II

NCT02942212
View directory record Official record
Conditions
Smoking Cessation
Interventions
Questionnaire, In-Depth Interviews, Breath Test, Nicotine Patches, Advice plus Phone Counseling, Advice plus Counseling Sessions, Self Assessment Questionnaires
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional

High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

NCT00002837
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

NCT03056339
View directory record Official record
Conditions
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, iC9/CAR.19/IL15-Transduced CB-NK Cells, AP1903
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
7 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 16, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT00065143
View directory record Official record
Conditions
Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions
clofarabine, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 74 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 16, 2026, 9:17 AM EDT